These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7684018)

  • 1. Assessment of lymphokine-activated killer activity and gamma-interferon production in patients with small hepatocellular carcinomas.
    Saibara T; Maeda T; Miyazaki M; Onishi S; Yamamoto Y
    Hepatology; 1993 May; 17(5):781-7. PubMed ID: 7684018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depressed immune function in patients with cirrhosis before emergence of hepatocellular carcinoma.
    Saibara T; Maeda T; Miyazaki M; Onishi S; Yamamoto Y
    Hepatology; 1993 Aug; 18(2):315-9. PubMed ID: 7687981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depressed lymphokine-activated killer activity and analysis of the precursor cells in peripheral blood of patients with hepatocellular carcinoma.
    Shirai M; Watanabe S; Nishioka M
    Hepatogastroenterology; 1990 Oct; 37(5):465-8. PubMed ID: 2174825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal immunomodulation in patients with hepatocellular carcinoma with lymphokine activated killer cells.
    Saibara T; Fujikawa M; Iwamura S; Matsuura Y; Ido E; Sakaeda H; Tomita A; Matsunaga Y; Maeda T; Onishi S
    Prog Clin Biol Res; 1990; 337():459-67. PubMed ID: 2162063
    [No Abstract]   [Full Text] [Related]  

  • 5. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.
    Hirofuji H; Kakumu S; Fuji A; Ohtani Y; Murase K; Tahara H
    Clin Exp Immunol; 1987 May; 68(2):348-56. PubMed ID: 2820634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional immunochemotherapy in hepatocellular carcinoma.
    Kountouras J; Boura P; Kouklakis G
    Hepatogastroenterology; 2002; 49(46):1109-12. PubMed ID: 12143214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma.
    Saibara T; Onishi S; Sakaeda H; Yamamoto Y
    Hepatology; 1989 Mar; 9(3):471-6. PubMed ID: 2537790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of interleukin-12-induced interferon-y production in vitro by peripheral blood mononuclear cells in patients with chronic liver disease.
    Imanishi H; Cheng J; Ikeda N; Saito M; Ohno M; Hara N; Shimomura S; Yamamoto T; Amuro Y; Fujiwara H; Hada T
    Hepatogastroenterology; 2003; 50(53):1502-5. PubMed ID: 14571773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of depressed lymphokine activated killer cell activity in patients with hepatocellular carcinoma.
    Saibara T; Onishi S; Matsuura Y; Fujikawa M; Sakaeda H; Matsunaga Y; Yamamoto Y
    Biotherapy; 1990; 2(1):1-12. PubMed ID: 2169282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Natural killer cell activity of the peripheral blood in patients with hepatocellular carcinoma].
    Lin ZY; Weng HZ; Tang ZY; Wang QD
    Zhonghua Zhong Liu Za Zhi; 1986 Nov; 8(6):417-20. PubMed ID: 2438105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction by OK-432 of lymphokine activated killer precursor cells in hepatocellular carcinoma.
    Aramaki M; Kim YI; Shimoda K; Nakashima K; Okada K; Kobayashi M
    Hepatogastroenterology; 1994 Aug; 41(4):363-6. PubMed ID: 7959572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma.
    Okumoto K; Hattori E; Tamura K; Kiso S; Watanabe H; Saito K; Saito T; Togashi H; Kawata S
    Liver Int; 2004 Feb; 24(1):21-8. PubMed ID: 15101997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Induction of anti-cancer cells and systemic immune response in hepatocellular carcinoma by OK-432].
    Aramaki M; Nakashima K; Sasaki A; Shimoda K; Yoshida T; Kim YI; Kitano S; Kobayashi M
    Gan To Kagaku Ryoho; 1994 Sep; 21(13):2115-7. PubMed ID: 7944416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Function of the immune system in liver cirrhosis].
    Bahr MJ; Manns MP
    Z Gastroenterol; 2001 Aug; 39(8):601-7. PubMed ID: 11558065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma.
    Nagao M; Nakajima Y; Kanehiro H; Hisanaga M; Aomatsu Y; Ko S; Tatekawa Y; Ikeda N; Kanokogi H; Urizono Y; Kobayashi T; Shibaji T; Kanamura T; Ogawa S; Nakano H
    Hepatology; 2000 Sep; 32(3):491-500. PubMed ID: 10960440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cimetidine reduces impairment of cellular immunity after transcatheter arterial embolization in patients with hepatocellular carcinoma.
    Nishiguchi S; Tamori A; Shiomi S; Enomoto M; Tatsumi N; Koh N; Habu D; Sakaguchi H; Takeda T; Seki S; Nakamura K; Kubo S; Kinoshita H
    Hepatogastroenterology; 2003; 50(50):460-2. PubMed ID: 12749247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
    Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
    J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
    Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
    Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.
    Alisa A; Ives A; Pathan AA; Navarrete CV; Williams R; Bertoletti A; Behboudi S
    Clin Cancer Res; 2005 Sep; 11(18):6686-94. PubMed ID: 16166448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.